While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the hundreds, all the way up to over $1,000 per share or more. At those steep prices, it is difficult to get any decent share count leverage.

Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.

Each week we screen our 24/7 Wall St. research database looking for stocks rated Buy at major firms and priced under the $10 level. This week we found five new stocks that could provide investors with some solid upside potential.

With the number of new equity traders skyrocketing over the past year due to the Reddit/WallStreetBets popularity, locating good ideas to trade has become even more challenging. These five could all prove to be exciting additions for traders looking for solid alpha potential. While they are definitely better suited for aggressive investors, it is still important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.

Ardmore Shipping

With the world economy starting to perk up, this could prove to be an outstanding idea. Ardmore Shipping Corp. (NYSE: ASC) engages in the seaborne transportation of petroleum products and chemicals worldwide. As of August 30, 2019, the company operated a fleet of 27 double-hulled product and chemical tankers. It serves oil majors, oil companies, oil and chemical traders and chemical companies.

On December 17, 2020, the company completed the previously announced $10.0 million loan facility for the Ardmore Seafarer, a 2010 Japanese MR product tanker delivered in August 2020, with Iyo Bank of Japan. The facility has a duration of five years and is priced at LIBOR plus a margin of 2.25%. The covenants and other conditions of the facility are consistent with those of Ardmore’s existing debt facilities.

Stifel has a $6 price target on the shares, and the Wall Street consensus target is $5.43. The shares slipped below $4 apiece on Friday.

With West Texas Intermediate crude going through the $60 a barrel level recently, this stock in the Great White North may be a solid energy idea. Cenovus Energy Inc. (NYSE: CVE) develops, produces and markets crude oil, natural gas liquids (NGLs) and natural gas in Canada, the United States and the Asia Pacific region.

The Oil Sands segment develops and produces bitumen in northeast Alberta. Its bitumen assets include Foster Creek, Christina Lake and Narrows Lake, as well as other projects in the early stages of development. The Conventional segment holds assets primarily located in Elmworth-Wapiti, Kaybob-Edson and Clearwater operating areas of British Columbia and Alberta, as well as various interests in natural gas processing facilities.

The Refining and Marketing segment transports and sells crude oil, natural gas and NGLs. This segment owns a 50% ownership in Wood River and Borger refineries located in the United States, and it owns and operates a crude-by-rail terminal in Alberta.

The Goldman Sachs price target of $9 is less than the $10.85 consensus target. Cenovus Energy stock has had a solid run and was trading north of $7 late in the week.

Charah Solutions

While way off the radar of many investors, this stock has big upside possibilities. Charah Solutions Inc. (NASDAQ: CHRA) provides environmental and maintenance services to the power generation industry in the United States. The company operates in the following two segments.

The Environmental Solutions segment offers remediation and compliance services, including development, construction and management of landfills for coal-fired power-generation facilities, and new and existing ash ponds, as well as active pond management services, such as clean closure, cap-in-place, and design and construction of new ponds.

The Maintenance and Technical Services segment provides fossil services, including coal ash management, silo management, on-site ash transportation, landfill management and capture and disposal of ash byproducts, as well as staffing solutions for coal-fired power generation facilities. It also manages combustion byproducts comprising bottom ash, as well as disposal of flue gas desulfurization gypsum, Pozatec/fixated scrubber sludge, and fluidized bed combustion fly ash.

Stifel’s $7 price target compares with a much lower $4.25 consensus target. The stock is up nicely year to date and was trading near $4 a share.

This is one for traders seeking a health care play. Infinity Pharmaceutical Inc. (NASDAQ: INFI) is a biopharmaceutical company that focuses on developing novel medicines for people with cancer.

It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma. Its product candidate IPI-549 is an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

The company has strategic alliances with the following:

• Intellikine, to discover, develop and commercialize pharmaceutical products targeting the delta or gamma isoforms of PI3K
• Verastem, to research, develop, commercialize and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
• PellePharm, to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate

It also has collaboration agreements with Arcus Biosciences, F. Hoffmann-La Roche and Bristol-Myers Squibb.

The $7 Piper Sandler price target is shy of the posted consensus target of $7.60. Infinity Pharmaceutical stock trended lower last week and was trading just over $3.

VistaGen Therapeutics

This is another biotech idea and it is priced like a call option for aggressive traders. VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company engaged in developing and commercializing various medicines with the potential to care for anxiety, depression and other disorders of the central nervous system (CNS).

The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 3 development for the acute treatment of anxiety in adults with social anxiety disorder. This product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic and others.

The company’s CNS pipeline also includes PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder. AV-101 is an oral N-methyl-D-aspartate receptor antagonist that is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia.

Jefferies recently upgraded the shares to Buy and has a $6 price target. The consensus target is $5.67. The stock recently gapped up over the $3 level but was last seen close to $2 a share.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.